Zanidatamab not checked

Jazz Pharmaceuticals · ZW25 · JZP598

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
11 active
16 in total · 12 in the EU
Targets
 

What this is

How it works
Blocks HER2, a growth signal on some breast and stomach cancer cells.Bispecific HER2-directed Antibody FDA class
Tested for
Breast Cancer (2 trials), Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma, Metastatic HER2-positive Breast Cancer, Biliary Tract Cancer, Gastric Cancer, Esophageal Cancer and 10 more
Main trialPhase 3
“This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).”In the company’s words, NCT05152147 on ClinicalTrials.gov
Other names
ZW25 · JZP598 · ZIIHERA

Other drugs for Breast Cancer

All 396 drugs for Breast Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 Jul 2026 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Phase 3Recruiting 28 Apr 2028 A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Phase 3Recruiting 1 Dec 2028 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Phase 2Recruiting 31 Dec 2026 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2Recruiting 29 Dec 2027 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Phase 2Completed 28 Apr 2023 Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Phase 2Completed 28 Jul 2023 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Phase 2Completed 30 Aug 2025 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Phase 1/2Completed 29 Aug 2025 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Phase 1Completed 31 Oct 2024 Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Phase 3Authorised not given SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial
Phase 1/2Authorised not given Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC)
Phase 2Authorised not given AcSé HER2_Widening treatment options among adult patients with HER2-overexpressing or mutant solid cancers
Phase 2Authorised not given ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Phase 1/2Authorised not given ​​Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial​
Phase 1/2Authorised not given PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zanidatamab

Following is part of Solo: you see every change to Zanidatamab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in